SGMO News and Press, Sangamo Therapeutics Inc. From 03/29/22

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate ...

Gainers: Adaptive Biotechnologies Corporation (ADPT) +5%. Angi  (ANGI) +5%. Sangamo Therapeutics (SGMO) +5%. Nikola Corporation (NKLA) +5%. Core Scientific (CORZ) +5%. Losers: ON Semiconductor Corporation (ON) -13%. Apellis Pharmaceuticals (APLS) -7%. Redbox Entertain...

Sangamo Therapeutics, Inc. (SGMO) Q4 2021 Earnings Conference Call February 24, 2022 04:30 PM ET Company Participants Aron Feingold - Head of Corporate Communications Sandy Macrae - CEO Mark McClung - COO Prathyusha Duraibabu - CFO Jason Fontenot - Chief Scientific Officer Rob Schott - Head o...

Sangamo Therapeutics' (NASDAQ:SGMO) Q4 2021 beats on the top and bottom lines has propelled the stock 5% higher in after-hours trading. The company's net loss in the quarter narrowed ~8% to ~$37.5M. Basic and diluted net loss per share was -$0.26, compared to -$0.29 in Q4 2020. Revenue increa...

The following slide deck was published by Sangamo Therapeutics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Sangamo Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation

Sangamo Therapeutics press release (NASDAQ:SGMO): Q4 GAAP EPS of -$0.26 beats by $0.09. Revenue of $28M (+8.5% Y/Y) beats by $0.64M. Cash, cash equivalents and marketable securities as of December 31, 2021 were $464.7 million, compared to $692.0 million as of December 31, 2020. "On a GAAP bas...

Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported fourth quarter and full year 2021 financial results and recent business highlights. “In 2021, we continued to ad...

SGMO, once an R&D powerhouse, hasn't been able to validate its platform with its clinical data. Its Hemophilia A durability data was underwhelming. I will stay on the sidelines until I see platform validation. For further details see: Sangamo Therapeutics: Lost In Tr...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2021 financial results after the market closes on Thursday, February 24, 2022. The press release will be followed by a co...

Sangamo Therapeutics (NASDAQ:SGMO) said preliminary data from a phase 1/2 study, dubbed STAAR, of its gene therapy isaralgagene civaparvovec (ST-920) continued to be well tolerated in patients with Fabry disease. Fabry disease is a rare inherited disorder of glycosphingolipid (fat) metab...